Business News, In Brief
Executive Summary
Updates on Sandoz' enoxaparin, J&J's Hep C business, Abbott and Watson.
You may also be interested in...
Sandoz GMP Warning Letter: Is The Problem Documentation, Or Leadership?
Upper management at Novartis and Sandoz are responsible for repeated cGMP violations at three Sandoz plants, FDA suggests. The agency’s warning letter, aimed at three sites in North Amercia, includes what may become new biolerplate instructions on drug shortages.
Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset
The planned purchase price of $11 billion, or $137 a share, an 89% premium over Pharmasset’s closing price on Nov. 18, is by far the highest ever paid for a clinical-stage biotech.
Abbott To Split Into Two Publicly Traded Companies Over Next 12 Months
Analysts see break-up as an effort to unlock value for proprietary pharmaceuticals unit, where expectations of slowing Humira sales may have left the company undervalued.